Letter to the Editor

On “Rise in Neonatal Abstinence Syndrome Rate Is Associated with Increase in Buprenorphine Prescription Numbers”

Authors: Satyam K. Ghodasara, BS, Hyo J. Yang, MD, Zoltan H. Nemeth, MD, PhD

Abstract

To the Editor: The article “Rise in Neonatal Abstinence Syndrome Rate Is Associated with Increase in Buprenorphine Prescription Numbers” by Shore et al in the December 2023 issue of the Southern Medical Journal sheds light on an important observation regarding the connection between buprenorphine prescriptions for pregnant patients and neonatal abstinence syndrome (NAS).

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Shore S, Lewis N, Olsen M. Rise in neonatal abstinence syndrome rate is associated with increase in buprenorphine prescription numbers. South Med J 2023;116:930–937.
 
2. Durling-Grover R, DiFazio LT, Adams JM, et al. New legislation in New Jersey reduced opioid use among trauma patients. J Opioid Manag 2023;19:133–137.
 
3. Martin CE, Shadowen C, Thakkar B, et al. Buprenorphine dosing for the treatment of opioid use disorder through pregnancy and postpartum. Curr Treat Options Psychiatry 2020;7:375–399.
 
4. Terplan M, Laird HJ, Hand DJ, et al. Opioid detoxification during pregnancy: a systematic review. Obstet Gynecol 2018;131:803–814.
 
5. Olsen M. Prevention of neonatal abstinence syndrome in an outpatient prenatal buprenorphine tapering program. South Med J 2020;113:553–558.